Adalvo Takes Over Romiplostim Biosimilar Program
The deal moves a peptibody copy of Amgen's NPLATE toward regulatory review, though no approval date has been set.
Updated on Nov. 6, 2026 in Biotech

Adalvo has acquired the romiplostim biosimilar program from Enzene, according to an announcement dated October 27, 2026. Romiplostim references Amgen's NPLATE, a thrombopoietin receptor agonist indicated for adult and chronic pediatric immune thrombocytopenia (ITP). The program is in development, so no approved biosimilar product is reported as available.
Why it matters
The deal combines Adalvo's global development, regulatory and commercial platform with Enzene's scientific and manufacturing expertise, a split that reflects how biosimilar development increasingly divides across firms. The program targets a peptibody-based biologic, an Fc-peptide fusion protein, which places it in a more specialized corner of biosimilar work than monoclonal antibody copies.
The program references Amgen's NPLATE, a peptibody that pairs an Fc-peptide fusion protein with thrombopoietin receptor agonist activity. No performance figures, comparator data, or measured results for the biosimilar were reported.
The players
Adalvo
A pharmaceutical company whose global development, regulatory and commercial platform is central to this acquisition of the romiplostim biosimilar program.
Enzene
A biosimilar developer whose scientific and manufacturing expertise and GMP-approved facilities in Pune, India, will continue to support the program.
Amgen
A biotechnology company whose NPLATE, the reference product for romiplostim, is indicated for adult and chronic pediatric immune thrombocytopenia.
The details
Romiplostim is a peptibody, a hybrid molecule that fuses a short synthetic peptide to an Fc fragment, the constant region of an antibody, which extends its time in the body. It acts as a thrombopoietin receptor agonist, meaning it mimics the body's natural signal to stimulate platelet production. Enzene will continue as the development and manufacturing partner, supplying product from its GMP-approved facilities in Pune, India, and will provide regulatory filing support to the United States Food and Drug Administration, the European Medicines Agency, and other international regulatory authorities.
Timeline
October 27, 2026: Adalvo announced the acquisition of Enzene's romiplostim biosimilar program.
The Tech Race
The program references NPLATE, the reference product from Amgen for treating immune thrombocytopenia. Its positioning sits within the wider competition to develop biosimilar copies of established biologic medicines.
The program remains in development, and no timeline for regulatory approval or commercial availability was reported. Patients with immune thrombocytopenia should not expect a new product from this deal in the near term.
The takeaway
Watch for regulatory filings with the United States Food and Drug Administration and the European Medicines Agency, which would indicate the program's progress toward approval. The next concrete milestone is a regulatory submission, which the source did not date.
Further reading
For broader context on how copies of established biologic drugs are developed, see the Biotech section.
Source note: This article includes information reported by Big Molecule Watch.


